Quarter
Charts

ABEONA THERAPEUTICS INC.

ABEO

CIK 0000318306 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$5M
Gross Profit
$4M

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
32/100
  • Profitability
    0ROIC -73.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 6.93 (above 1.5 = solid)
  • Leverage
    94D/E 0.13 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.04x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$8M
investment in PP&E
Stock-based comp (TTM)
$11M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$220M
everything owned
Total liabilities
$60M
everything owed
Stockholders' equity
$159M
shareholder claim
Net debt
$-58M
Net cash position ($58M)

Recent performance · 63 quarters

Revenue
$5M
Net Income↑+82.9% +$25M
$-5M
Free Cash Flow↓-90.3% -$547K
$-1M
Operating Margin
-5698.0%

Drill down

ABEO Sankey

See ABEONA THERAPEUTICS INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ABEO Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ABEO Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics